Vulvovaginal Disease

Vaginal yeast infections were successfully treated with berberine, a biologically active herbal alkaloid, according to a study published in Frontiers in Pharmacology.

A study published in Frontiers in Cellular and Infection Microbiology observed significant vaginal microbiome alterations in patients with bacterial vaginosis (BV) plus vulvovaginal candidiasis (VVC) mixed vaginitis before and after drug treatment.

Currently approved for the treatment of vulvovaginal candidiasis (VVC), and if the sNDA is approved, ibrexafungerp (Brexafemme; Scynexis) would be the first and only oral non-azole medication for the prevention of recurrent VVC.

The research published in the Journal of Clinical Medicine found women were more likely to have infections in the summer.

In June 2021, ibrexafungerp (Brexafemme; Scynexis) became the first drug approved by the U.S. Food and Drug Administration (FDA) in a novel antifungal class in more than 20 years and is now available to treat vulvovaginal candidiasis (VVC).

The US Food and Drug Administration has approved oteseconazole (Vivjoa; Mycovia Pharmaceuticals) to reduce the incidence of recurrent vulvovaginal candidiasis.

Vulvovaginal candidiasis (VVC)—commonly known as a yeast infection—is a problem many women face at some point. About half of all women have had at least 1 of these infections clinical diagnosed, and between 6% and 10% are believed to develop a recurrent form of this condition with 3 to 4 or more episodes in a single year, according to a new report.

The VMB may be a biological barrier to pathogenic microorganisms. There is also an increased risk of acquiring various vaginal pathogens when the dominant lactobacilli community is disrupted.

Women with bacterial vaginosis (BV) and/or vulvovaginal candidiasis (VVC) were significantly less likely to use intimate soap and moist wipes after urination compared to healthy women without any vulvovaginal symptoms, according to a cross-sectional study published in the journal Revista Brasileira de Ginecologia e Obstetricia.

Not only does vulvodynia impact a woman’s sexual and psychological health, but it also places significant financial burden on those seeking treatment.

Using bactericidal soaps and sex toys and having anal sex were associated with higher rates of bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC), according to a study in RBGO Gynecology and Obstetrics (Revista Brasileira de Ginecologia e Obstetricia). However, study authors caution, identifying these associations do not establish causality.

A study published in Women’s Health Reports suggests best practices for treating recurrent vulvovaginal candidiasis.

The incidences of vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV) are especially high in young women, and women with a limited education and low-family income, according to a nationwide cohort study in the International Journal of Infectious Diseases.

The incidences of vulvovaginal candidiasis (VVC) and bacterial vaginosis (BV) are especially high in young women, and women with a limited education and low-family income, according to a nationwide cohort study in the International Journal of Infectious Diseases.

Patients with acute vulvovaginal candidiasis (VVC) greatly benefited from oral ibrexafungerp (Brexafemme, Scynexis), according to results of a global phase 3 randomized, double-blind, placebo-controlled superiority study published in the international journal of obstetrics and gynecology, BJOG.

Postmenopausal vaginal symptom severity is not significantly linked to vaginal microbiota or mucosal inflammatory markers, according to a small study in the American Journal of Gynecology & Obstetrics.

Scynexis released data from its pivotal Phase 3 CANDLE study of oral ibrexafungerp (BREXAFEMME) for the prevention of recurrent vulvovaginal candidiasis.

A different perspective on designing transfersomal nanocarriers of nystatin to treat vulvovaginal candidiasis (VVC) is reflected in a prospective in-vitro study in the journal Colloids and Surfaces B: Biointerfaces.

Research in the journal Cell Reports concludes that the discovery of a hormone-sensing pathway in Candida albicans, which enables the fungus to adapt to estrogen, could help explain gender biases linked to fungal infections and might provide an alternative approach to improving women's health.

Women with non-albicans Candida (NAC) vulvovaginal candidiasis (VVC) were nearly twice as likely to have multiple physician visits for recurring infections compared to women who had C. albicans (CA) VVC, according to a retrospective chart review in the Journal of Women’s Health.

An oral probiotic formula for the secondary prevention of vulvovaginal infections in pregnant women neither colonized in the vagina nor reduced the rate of repeated vulvovaginal infection, according to a study in the American Journal of Gynecology & Obstetrics.

A clinical study has confirmed that the pathophysiology of recurrent vulvovaginal candidiasis (RVVC) relies primarily on Candida albicans (C. albicans)-specific attributes like hyphal morphogenesis, biofilm formation and pathogenesis that differentiate it from other prominent non-albicans C. (NAC) species.

Among women with vulvovaginal candidiasis (VVC) or recurrent VVC (RVVC), the 3 most common signs and symptoms are itching (91.2%), burning (68.3%), and redness (58.1%), according to an online patient survey in BMC Womens Health.

Because the mechanism of action of medical-grade honey (MGH) is based on enhancing wound healing and exerting strong broad-spectrum antimicrobial activity, MGH may also help to treat recurrent vulvovaginal candidiasis (RVVC), according to a review in the Journal of Fungi.

To the investigators’ surprise, routine perinatal visits had the greatest impact on PROM in pregnant women with VVC.

Lactobacilli are the presiding members of the healthy human vaginal microbiota and are considered the first defense line from pathogen infection, including vulvovaginal candidiasis (VVC), whereas biofilm is the predominant microbial growth form in nature.

A home kit to detect urinary tract infections (UTIs) like Candida albicans from vaginal fluids on sanitary napkins and tampons could soon enter the clinical phase.

The benefits of probiotics do not necessarily transfer to the clinical setting for vulvovaginal candidiasis, according to a recent review.

A recent study found ibrexafungerp (Brexafemme, Scynexis) was found to be a well-tolerated novel antifungal with similar efficacy to fluconazole for treating acute vulvovaginal candidiasis.

Ibrexafungerp (Brexafemme; Scynexis) therapy has cleared signs and symptoms of vaginal yeast infection in 73.9% of patients in a recent study.